{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-23-000089","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.263286+00:00","generated_at":"2026-06-09T00:40:18.991435+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allogene reports Q3 net loss $61.3M; cash $497.7M; ALPHA2 on track","bullets":["Net loss of $61.3M ($0.37/sh) for Q3 2023; R&D expense $46.0M, G&A $17.0M.","Cash, equivalents and investments $497.7M as of Sept 30, 2023; runway into 2H 2025.","2023 guidance: cash use ~$230M; GAAP op. expense ~$340M incl. ~$80M stock comp.","ALPHA2 Phase 2 trial for ALLO-501A in LBCL enrolling; completion expected 1H 2024, data by end 2024.","New CFO Geoffrey Parker and General Counsel Earl Douglas appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-23-000089","json":"https://secwatch.observer/filing/0001737287-23-000089.json","markdown":"https://secwatch.observer/filing/0001737287-23-000089.md","text":"https://secwatch.observer/filing/0001737287-23-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000089/0001737287-23-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000089/allo-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:40:18.991435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"716b42930ff92cdeb9b2f1cde9725d26139bbc4b","claim":"Allogene Therapeutics, Inc. reported financial results for for the quarter ended September 30, 2023.","evidence_excerpt":"Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000089/0001737287-23-000089-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}